NO844528L - Omega-cykloalkylprostaglandiner og fremgangsmaate for deres fremstilling. - Google Patents
Omega-cykloalkylprostaglandiner og fremgangsmaate for deres fremstilling.Info
- Publication number
- NO844528L NO844528L NO844528A NO844528A NO844528L NO 844528 L NO844528 L NO 844528L NO 844528 A NO844528 A NO 844528A NO 844528 A NO844528 A NO 844528A NO 844528 L NO844528 L NO 844528L
- Authority
- NO
- Norway
- Prior art keywords
- hydroxy
- methyl
- cis
- trans
- oxocyclopentane
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 30
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 23
- 239000001257 hydrogen Substances 0.000 claims abstract description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims abstract description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 9
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000005977 Ethylene Substances 0.000 claims abstract description 7
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims abstract description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 abstract description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- -1 alkyl radical Chemical class 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 230000001262 anti-secretory effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 230000001120 cytoprotective effect Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- YRLAELHRQPTDAX-UHFFFAOYSA-N 4-cyclopentylbutan-2-one Chemical compound CC(=O)CCC1CCCC1 YRLAELHRQPTDAX-UHFFFAOYSA-N 0.000 description 3
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KAANTNXREIRLCT-UHFFFAOYSA-N 1-(triphenyl-$l^{5}-phosphanylidene)propan-2-one Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)C)C1=CC=CC=C1 KAANTNXREIRLCT-UHFFFAOYSA-N 0.000 description 2
- LPRBSWPDOZIDQE-UHFFFAOYSA-N 4-cyclopropylbutan-2-one Chemical compound CC(=O)CCC1CC1 LPRBSWPDOZIDQE-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BUIQRTDBPCHRIR-UHFFFAOYSA-L O[Cr](Cl)(=O)=O Chemical compound O[Cr](Cl)(=O)=O BUIQRTDBPCHRIR-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IPBXRBOBBINJKN-UHFFFAOYSA-N (1-cyclopropyl-3-methylhex-5-yn-3-yl)oxy-trimethylsilane Chemical compound C#CCC(O[Si](C)(C)C)(C)CCC1CC1 IPBXRBOBBINJKN-UHFFFAOYSA-N 0.000 description 1
- PIZQWRXTMGASCZ-UHFFFAOYSA-N (1-methylcyclopropyl)methanol Chemical compound OCC1(C)CC1 PIZQWRXTMGASCZ-UHFFFAOYSA-N 0.000 description 1
- FAAMQFFTSATJRM-ONEGZZNKSA-N (e)-4-(1-methylcyclopropyl)but-3-en-2-one Chemical compound CC(=O)\C=C\C1(C)CC1 FAAMQFFTSATJRM-ONEGZZNKSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- YYJCNNFQNIAISZ-UHFFFAOYSA-N 1-cyclopentylpropan-2-one Chemical compound CC(=O)CC1CCCC1 YYJCNNFQNIAISZ-UHFFFAOYSA-N 0.000 description 1
- LEFXWSGHLDDUHA-UHFFFAOYSA-N 1-cyclopropyl-3-methylhex-5-yn-3-ol Chemical compound C#CCC(O)(C)CCC1CC1 LEFXWSGHLDDUHA-UHFFFAOYSA-N 0.000 description 1
- NCJXPECBGWEDFS-UHFFFAOYSA-N 1-methylcyclobutane-1-carbaldehyde Chemical compound O=CC1(C)CCC1 NCJXPECBGWEDFS-UHFFFAOYSA-N 0.000 description 1
- DOJZSEYEQKWUSI-UHFFFAOYSA-N 1-methylcyclopropane-1-carbaldehyde Chemical compound O=CC1(C)CC1 DOJZSEYEQKWUSI-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- CRMSNXKNXNDOHJ-UHFFFAOYSA-N 4-(1-methylcyclobutyl)but-3-en-2-one Chemical compound CC(=O)C=CC1(C)CCC1 CRMSNXKNXNDOHJ-UHFFFAOYSA-N 0.000 description 1
- FAAMQFFTSATJRM-UHFFFAOYSA-N 4-(1-methylcyclopropyl)but-3-en-2-one Chemical compound CC(=O)C=CC1(C)CC1 FAAMQFFTSATJRM-UHFFFAOYSA-N 0.000 description 1
- WFGYHDUDDGCXIV-UHFFFAOYSA-N 4-cyclobutylbut-3-en-2-one Chemical compound CC(=O)C=CC1CCC1 WFGYHDUDDGCXIV-UHFFFAOYSA-N 0.000 description 1
- CJQLXYNXAPVUHE-UHFFFAOYSA-N 4-cyclobutylbutan-2-one Chemical compound CC(=O)CCC1CCC1 CJQLXYNXAPVUHE-UHFFFAOYSA-N 0.000 description 1
- SXIFUCHHJQLNCT-UHFFFAOYSA-N 4-cyclopentylbut-3-yn-2-one Chemical compound CC(=O)C#CC1CCCC1 SXIFUCHHJQLNCT-UHFFFAOYSA-N 0.000 description 1
- RNDVGJZUHCKENF-UHFFFAOYSA-N 5-hexen-2-one Chemical compound CC(=O)CCC=C RNDVGJZUHCKENF-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- RJMZWYURQZUXHT-UHFFFAOYSA-N butan-2-yl-chloro-dimethylsilane Chemical compound CCC(C)[Si](C)(C)Cl RJMZWYURQZUXHT-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- TZVCKDHEEWNZDE-UHFFFAOYSA-N copper;pent-1-yne Chemical compound [Cu].CCCC#C TZVCKDHEEWNZDE-UHFFFAOYSA-N 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002416 diarrheagenic effect Effects 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BSYCQORECWMSQX-UHFFFAOYSA-N hept-6-en-3-one Chemical compound CCC(=O)CCC=C BSYCQORECWMSQX-UHFFFAOYSA-N 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- HWHPNCYVVJDMOE-UHFFFAOYSA-N methyl 1-methylcyclobutane-1-carboxylate Chemical compound COC(=O)C1(C)CCC1 HWHPNCYVVJDMOE-UHFFFAOYSA-N 0.000 description 1
- CBTGNLZUIZHUHY-UHFFFAOYSA-N methyl cyclobutanecarboxylate Chemical compound COC(=O)C1CCC1 CBTGNLZUIZHUHY-UHFFFAOYSA-N 0.000 description 1
- UYYCVBASZNFFRX-UHFFFAOYSA-N n-propan-2-ylcyclohexanamine Chemical compound CC(C)NC1CCCCC1 UYYCVBASZNFFRX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/551,238 US4499296A (en) | 1983-11-14 | 1983-11-14 | Omega cycloalkyl prostaglandins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO844528L true NO844528L (no) | 1985-05-15 |
Family
ID=24200423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO844528A NO844528L (no) | 1983-11-14 | 1984-11-13 | Omega-cykloalkylprostaglandiner og fremgangsmaate for deres fremstilling. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4499296A (xx) |
| EP (1) | EP0142158B1 (xx) |
| JP (1) | JPS60116667A (xx) |
| AT (1) | ATE39481T1 (xx) |
| AU (1) | AU3536084A (xx) |
| DE (1) | DE3475785D1 (xx) |
| DK (1) | DK538984A (xx) |
| ES (1) | ES8603400A1 (xx) |
| FI (1) | FI844460L (xx) |
| GR (1) | GR80926B (xx) |
| IL (1) | IL73501A (xx) |
| NO (1) | NO844528L (xx) |
| NZ (1) | NZ210197A (xx) |
| PH (1) | PH21604A (xx) |
| PT (1) | PT79488A (xx) |
| ZA (1) | ZA848840B (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713477A (en) * | 1983-11-14 | 1987-12-15 | G. D. Searle & Co. | Omega cycloalkyl prostaglandins |
| GB8410396D0 (en) * | 1984-04-24 | 1984-05-31 | Glaxo Group Ltd | Carbocyclic compounds |
| DE3526362A1 (de) * | 1985-07-19 | 1987-01-22 | Schering Ag | Prostacycline, ihre analoga oder prostaglandine und thromboxanantagonisten zur behandlung von thrombotischen und thromboembolischen krankheitsbildern |
| EP0213313A3 (en) * | 1985-07-29 | 1988-09-14 | American Cyanamid Company | Precursors and synthesis of methyl-9-oxo-11 alpha, 16-dihydroxy-16-vinyl-5-cis-13-trans prostadienoates |
| US4820728A (en) * | 1985-11-25 | 1989-04-11 | G. D. Searle & Co. | Tetraenyl prostaglandins |
| US4847293A (en) * | 1985-11-25 | 1989-07-11 | G. D. Searle & Co. | Tetraenyl prostaglandins |
| US4683328A (en) * | 1985-11-25 | 1987-07-28 | G. D. Searle & Co. | Tetraenyl prostaglandins |
| US5011958A (en) * | 1987-06-08 | 1991-04-30 | G. D. Searle & Co. | Process for preparing higher order cuprate complexes |
| US4785124A (en) * | 1987-06-08 | 1988-11-15 | G. D. Searle & Co. | Process for preparing higher order cuprate complexes |
| US4777275A (en) * | 1987-06-09 | 1988-10-11 | G. D. Searle & Co. | Process of preparing higher order cuprate complexes |
| ES2069821T3 (es) * | 1990-02-26 | 1995-05-16 | R Tech Ueno Ltd | Nuevas 15-deshidroxi-16-oxoprostaglandinas. |
| US5177251A (en) * | 1991-12-24 | 1993-01-05 | G. D. Searle & Co. | Halogenated tetraenyl prostaglandin derivatives |
| JP2531341Y2 (ja) * | 1993-02-25 | 1997-04-02 | 小糸工業株式会社 | 衛生洗浄装置におけるワイヤレスリモコン装置 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3965143A (en) * | 1974-03-26 | 1976-06-22 | G. D. Searle & Co. | 16-Oxygenated prostanoic acid derivatives |
| US4281153A (en) * | 1977-08-01 | 1981-07-28 | American Cyanamid | 15-Deoxy-16-hydroxy-16-substituted prostanoic acids and congeners |
| US4275224A (en) * | 1978-02-23 | 1981-06-23 | Miles Laboratories, Inc. | 15-Deoxy-16-hydroxy prostaglandins |
| US4271314A (en) * | 1979-11-28 | 1981-06-02 | G. D. Searle & Co. | 4,5-Unsaturated prostanoic acid derivatives |
-
1983
- 1983-11-14 US US06/551,238 patent/US4499296A/en not_active Expired - Lifetime
-
1984
- 1984-11-13 EP EP84113676A patent/EP0142158B1/en not_active Expired
- 1984-11-13 AU AU35360/84A patent/AU3536084A/en not_active Abandoned
- 1984-11-13 NO NO844528A patent/NO844528L/no unknown
- 1984-11-13 DK DK538984A patent/DK538984A/da not_active Application Discontinuation
- 1984-11-13 JP JP59239323A patent/JPS60116667A/ja active Granted
- 1984-11-13 NZ NZ210197A patent/NZ210197A/en unknown
- 1984-11-13 AT AT84113676T patent/ATE39481T1/de not_active IP Right Cessation
- 1984-11-13 ES ES537613A patent/ES8603400A1/es not_active Expired
- 1984-11-13 FI FI844460A patent/FI844460L/fi not_active Application Discontinuation
- 1984-11-13 IL IL73501A patent/IL73501A/xx unknown
- 1984-11-13 DE DE8484113676T patent/DE3475785D1/de not_active Expired
- 1984-11-13 ZA ZA848840A patent/ZA848840B/xx unknown
- 1984-11-13 PT PT79488A patent/PT79488A/pt unknown
- 1984-11-13 PH PH31444A patent/PH21604A/en unknown
- 1984-11-13 GR GR80926A patent/GR80926B/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI844460A0 (fi) | 1984-11-13 |
| FI844460L (fi) | 1985-05-15 |
| ATE39481T1 (de) | 1989-01-15 |
| GR80926B (en) | 1985-02-26 |
| EP0142158A3 (en) | 1986-09-03 |
| ES537613A0 (es) | 1985-12-16 |
| IL73501A0 (en) | 1985-02-28 |
| JPH0576467B2 (xx) | 1993-10-22 |
| EP0142158A2 (en) | 1985-05-22 |
| DK538984A (da) | 1985-05-15 |
| ZA848840B (en) | 1985-12-24 |
| DK538984D0 (da) | 1984-11-13 |
| US4499296A (en) | 1985-02-12 |
| PH21604A (en) | 1987-12-11 |
| EP0142158B1 (en) | 1988-12-28 |
| IL73501A (en) | 1987-12-31 |
| JPS60116667A (ja) | 1985-06-24 |
| AU3536084A (en) | 1985-05-23 |
| PT79488A (en) | 1984-12-01 |
| ES8603400A1 (es) | 1985-12-16 |
| DE3475785D1 (en) | 1989-02-02 |
| NZ210197A (en) | 1988-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2513212A1 (de) | 16-oxidierte prostansaeurederivate und verfahren zu deren herstellung | |
| NO844528L (no) | Omega-cykloalkylprostaglandiner og fremgangsmaate for deres fremstilling. | |
| CH647222A5 (de) | 9-desoxy-9a-methylen-isostere von pgi-2 und verfahren zu deren herstellung. | |
| AU766163B2 (en) | C16 unsaturated fp-selective prostaglandins analogs | |
| KR20010102509A (ko) | Ｃ16 불포화 ｆｐ 선택적 프로스타글란딘 유사체 | |
| US4529812A (en) | 3-Oxaprostaglandins | |
| EP0051558B1 (de) | Prostacyclinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| US4683328A (en) | Tetraenyl prostaglandins | |
| US4820728A (en) | Tetraenyl prostaglandins | |
| US4578505A (en) | Allenic prostanoic acid derivatives | |
| DE3121155A1 (de) | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| US4863961A (en) | Tetraenyl prostaglandins | |
| US4754059A (en) | Omega cycloalkyl prostaglandins | |
| US4536592A (en) | 2-Substituted prostaglandins | |
| US4847293A (en) | Tetraenyl prostaglandins | |
| US4713477A (en) | Omega cycloalkyl prostaglandins | |
| DE2746932A1 (de) | 5,9-cyclische aether von 9-deoxy- prostaglandin-f tief 1alpha -artigen verbindungen und verfahren zu deren herstellung | |
| DD140745A5 (de) | Verfahren zur herstellung von neuen prostaglandinen | |
| NO820983L (no) | Alfa-dien 16-hydroksyprostansyrederivater og fremgangsmaate til deres fremstilling | |
| DE2813342A1 (de) | 15-deoxy-16-hydroxy-16-substituierte-prostansaeuren, derivate hiervon und verfahren zu ihrer herstellung | |
| DE2709347A1 (de) | Erythro-15,16-dioxyprostensaeuren und -ester sowie verfahren zu ihrer herstellung | |
| US4254036A (en) | 1-Hydroxymethyl-1-oxo-prostane-derivatives of the E, A and F-series | |
| US4617411A (en) | 3-oxaprostaglandins | |
| US5177251A (en) | Halogenated tetraenyl prostaglandin derivatives | |
| NL7810862A (nl) | 5 6-didehydroprostacycline-analoga, farmaceutische preparaten daarvan en werkwijzen voor het bereiden van een en ander. |